In biotech, when you hear that a drug's peak sales estimates hover around $200 million, usually you shrug. But for a stock like Amicus Therapeutics (NASDAQ:FOLD), with a market cap of under $300 million, suddenly $200 million in potential sales looks like a big deal.

Amicus announced yesterday that it would be reporting data from its phase 3 study (titled "Study 012") for Migalast HCL for Fabry Disease sometime in third quarter. And today shareholders got even better news, as analysts moved their price targets on the stock, reflecting increasing market optimism that this drug will perform well.

But is the stock a good investment? In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their two cents on Amicus.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.